MAZE vs ACMR vs ICHR vs RARE vs MKSI

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Maze Therapeutics, Inc. (MAZE). ACM Research, Inc. (ACMR) offers the better valuation at 68. 6x trailing P/E (47. 1x forward), making it the more compelling value choice. Analysts rate Maze Therapeutics, Inc. (MAZE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACM Research, Inc.

(ACMR) is the cheapest at 68. 6x versus MKS Inc. at 81. 4x. On forward P/E, MKS Inc. is actually cheaper at 30. 4x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, ACM Research, Inc.

(ACMR) delivered a total return of +192. 4%, compared to -76. 3% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: ACMR returned +49. 2% versus RARE's -59. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Maze Therapeutics, Inc.

(MAZE) is the lower-risk stock at 1. 13β versus Ichor Holdings, Ltd. 's 3. 97β — meaning ICHR is approximately 252% more volatile than MAZE relative to the S&P 500. On balance sheet safety, Maze Therapeutics, Inc. (MAZE) carries a lower debt/equity ratio of 7% versus 173% for MKS Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -100. 0% for Maze Therapeutics, Inc. (MAZE). On earnings-per-share growth, the picture is similar: MKS Inc. grew EPS 55. 5% year-over-year, compared to -40. 2% for Maze Therapeutics, Inc.. Over a 3-year CAGR, ACMR leads at 32. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACM Research, Inc.

(ACMR) is the more profitable company, earning 10. 4% net margin versus -612. 7% for Maze Therapeutics, Inc. — meaning it keeps 10. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MKSI leads at 14. 4% versus -670. 3% for MAZE. At the gross margin level — before operating expenses — MAZE leads at 92. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, MKS Inc.

(MKSI) trades at 30. 4x forward P/E versus 63. 0x for Ichor Holdings, Ltd. — 32. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MAZE: 163. 0% to $63. 25.

In this comparison, MKSI (0.

2% yield), ACMR (0. 1% yield) pay a dividend. MAZE, ICHR, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Maze Therapeutics, Inc.

(MAZE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13)). ACM Research, Inc. (ACMR) carries a higher beta of 3. 46 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MAZE: +50. 8%, ACMR: +49. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MAZE (Healthcare) and ACMR (Technology) and ICHR (Technology) and RARE (Healthcare) and MKSI (Technology)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MAZE is a small-cap quality compounder stock; ACMR is a small-cap high-growth stock; ICHR is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; MKSI is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.